Takeda Pharma (TKPYY) 21.5450 $TKPYY
Takeda Responds to Ruling in Diabetes Drug Case
PR Newswire - Mon Oct 27, 5:41PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that Judge Rebecca Doherty reduced the punitive damage award in Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064) from $6 billion against Takeda and $3 billion against Eli Lilly to $27.65 million against Takeda and $9.22 million against Eli Lilly. Compensatory damages were previously reduced from $1.475 million to $1.27 million. The court entered a judgment reflecting these amounts.
LLY: 64.83 (-1.37)
Mersana and Takeda Enter Commercial License Agreement for Novel Fleximer(R) Antibody-Drug Conjugate
Business Wire - Mon Oct 27, 7:01AM CDT
Mersana Therapeutics, Inc., announced today that Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), has exercised an option to license commercial rights for its first novel Fleximer(R) antibody-drug conjugate (ADC) developed under their collaboration announced earlier this year. Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana's Fleximer-ADC technology. With the exercise of the commercial license, Mersana will receive a license fee and is eligible for development and regulatory milestone payments and royalties on net sales.
Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
PR Newswire - Mon Oct 20, 7:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda" , its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Contrave is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia).
OREX: 4.19 (+0.14)
Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Thu Oct 16, 12:37PM CDT
Orexigen announced that it has earned a milestone payment of $70 million from its partner Takeda Pharmaceutical Company Limited.
MDVN: 101.18 (-1.57), OREX: 4.19 (+0.14), LGND: 51.89 (-2.34)
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
GlobeNewswire - Tue Oct 14, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the United States (U.S.) and Canada for AMITIZA (lubiprostone) with Takeda Pharmaceutical Company Ltd. (Takeda). The amendment includes various modifications to the Collaboration Agreement including the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.
SCMP: 8.35 (+0.02)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 53.16 (+1.70), SCMP: 8.35 (+0.02), RDY: 50.72 (-0.32)
Unstable Angina Therapeutics Clinical Trials Market Review Report Available at MarketOptimizer.org
PRWeb - Sun Oct 12, 2:30PM CDT
Unstable angina is angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm. It is characterized by at least one of the following: Occurs at rest or minimal exertion and usually lasts less than 20 minutes (if nitroglycerin is not administered) Being severe and described as flank pain, and of new onset (i.e., within 1 month) Occurs with a crescendo pattern (more severe, prolonged, or increased frequency than previously). Fifty percent of people with unstable angina will have evidence of myocardial necrosis based on elevated cardiac serum markers such as creatine kinase isoenzyme (CK)-MB and troponin T or I, and thus have a diagnosis of non-ST elevation myocardial infarction. Clinical trial report, "Unstable Angina Global Clinical Trials Review, H2, 2014″ provides data on the Unstable Angina clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Unstable Angina. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Unstable Angina. Complete report available @ http://www.marketoptimizer.org/unstable-angin...-2014.html . Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated) Reasons To Buy Understand the dynamics of a particular indication in a condensed manner Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=11399 . Clinical Trial Overview of Top Companies: Sanofi Takeda Pharmaceutical Company Limited AstraZeneca PLC Pfizer Inc GlaxoSmithKline plc Biopure Corporation (Inactive) AtheroGenics, Inc. (Inactive) Alere Inc. Ablynx NV Clinical Trial Overview of Top Institutes / Government: National Heart, Lung, and Blood Institute China Academy of Chinese Medical Sciences Massachusetts General Hospital Karolinska Institute Nanjing Medical University Deutsches Herzzentrum Munchen Semnan University of Medical Sciences Kanagawa PTCA Conference Population Health Research Institute University of Oslo
PFE: 29.09 (+0.06), AZN: 71.43 (+0.67), GSK: 45.10 (-0.27), ALR: 39.12 (+1.55)
The Sixth Actos Verdict has been made in Favor of a Man Who Developed Bladder Cancer After Taking the Diabetes Medication, Parker Waichman LLP Comments
PRWeb - Fri Oct 10, 8:02AM CDT
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications reports that a jury has awarded another multi-million dollar settlement in a lawsuit brought over Takeda Pharmaceutical Co. Ltd.'s diabetes drug, Actos (pioglitazone). The case is Frances Wisniewski v. Takeda Pharmaceuticals America Inc. et al., case number 120702272, in the Philadelphia County Court of Common Pleas.
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA(R) and Company Receives Additional Paragraph IV Notice
Business Wire - Fri Oct 10, 12:51AM CDT
R-Tech Ueno (JASDAQ:4573):
SCMP: 8.35 (+0.02)
Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA
GlobeNewswire - Thu Oct 09, 3:45PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo, R-Tech Ueno, Ltd. (RTU), Takeda Pharmaceutical Company Limited (Takeda) and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc., (collectively, Par) that resolves patent litigation in the United States (U.S.) related to Sucampo's AMITIZA(lubiprostone) 8 mcg and 24 mcg soft gelatin capsules.
SCMP: 8.35 (+0.02)
Global Idiopathic (Essential) Hypertension Clinical Trials Review 2014 - Featuring the Top 10 Companies and 9 Institutues
M2 - Thu Oct 02, 5:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq9cbf/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials - Novartis AG - C. H. Boehringer Sohn AG & Co. KG - Takeda Pharmaceutical Company Limited - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Medionics International Inc - Bayer AG - GlaxoSmithKline plc - Pfizer Inc. - Les Laboratoires Servier SAS Overview of Top Institutes / Government - Institut de Recherches Internationales Servier - Regional Hospital Holstebro - National Heart, Lung, and Blood Institute - University of Erlangen-Nurnberg - University of Pavia - St. George's University of London - Central South University - Ehime University Graduate School of Medicine - Komono Kosei Hospital For more information visit http://www.researchandmarkets.com/research/vq9cbf/idiopathic
PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Seattle Genetics-Takeda Reveal Impressive Adcetris Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 2:30PM CDT
Seattle Genetics, Inc. (SGEN) and partner Takeda announced positive top-line data from the randomized phase III AETHERA study on Adcetris for Hodgkin lymphoma.
MDVN: 101.18 (-1.57), SGEN: 36.37 (+0.98), GILD: 113.45 (+0.86)
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
Business Wire - Thu Sep 25, 12:15PM CDT
Takeda Pharmaceutical Company Limited ("Takeda" and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly announced today that Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.
Influenza B Infections Pipeline Review 2014 - 8 Companies & 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jk252h/influenza_b) has announced the addition of the "Influenza B Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Autoimmune Technologies, LLC - Takeda Pharmaceutical Company Limited - Crucell N.V. - Chimerix, Inc. - REPLICor Inc. - AltraVax Inc. - ContraFect Corporation - Humabs BioMed SA Drug Profiles - REP-9 - Influenza VLP Vaccine - Flufirvitide-3 - CF-403 - CR-8071 - CR-8033 - CR-9114 - Small Molecules for Influenza B - Monoclonal Antibody for Influenza B Infections - AL-18 - influenza B vaccine For more information visit http://www.researchandmarkets.com/research/jk...nfluenza_b
CMRX: 31.44 (-0.52)
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:10PM CDT
Novo Nordisk's (NVO) Saxenda received a favorable vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for chronic weight management.
AGN: 182.60 (+0.27), OREX: 4.19 (+0.14), NVO: 43.50 (-2.30)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
SNTA: 2.95 (+0.01), AMBI: 15.45 (+0.05), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
PSTI: 2.94 (+0.03), PFE: 29.09 (+0.06), ABBV: 60.93 (+0.44), PTIE: 2.07 (+0.12), ARRY: 3.84 (+0.27)
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
GSK: 45.10 (-0.27), SVA: 5.42 (+0.02), NVS: 92.35 (+2.14)
Takeda Responds to Judgment in Diabetes Drug Case
PR Newswire - Wed Sep 03, 12:37PM CDT
Takeda Pharmaceutical Company Limited ("Takeda" and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court has yet to rule on Takeda and Eli Lilly & Co.'s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award.
LLY: 64.83 (-1.37)
Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
JNJ: 104.79 (+0.72), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), HZNP: 12.85 (+0.16), POZN: 8.82 (+0.08)
Takeda Responds to Ruling in Diabetes Drug Case
PR Newswire - Mon Oct 27, 5:41PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that Judge Rebecca Doherty reduced the punitive damage award in Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064) from $6 billion against Takeda and $3 billion against Eli Lilly to $27.65 million against Takeda and $9.22 million against Eli Lilly. Compensatory damages were previously reduced from $1.475 million to $1.27 million. The court entered a judgment reflecting these amounts. LLY: 64.83 (-1.37)
Mersana and Takeda Enter Commercial License Agreement for Novel Fleximer(R) Antibody-Drug Conjugate
Business Wire - Mon Oct 27, 7:01AM CDT
Mersana Therapeutics, Inc., announced today that Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), has exercised an option to license commercial rights for its first novel Fleximer(R) antibody-drug conjugate (ADC) developed under their collaboration announced earlier this year. Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana's Fleximer-ADC technology. With the exercise of the commercial license, Mersana will receive a license fee and is eligible for development and regulatory milestone payments and royalties on net sales.
Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
PR Newswire - Mon Oct 20, 7:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
, its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Contrave is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). OREX: 4.19 (+0.14)
Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Thu Oct 16, 12:37PM CDT
Orexigen announced that it has earned a milestone payment of $70 million from its partner Takeda Pharmaceutical Company Limited.
MDVN: 101.18 (-1.57), OREX: 4.19 (+0.14), LGND: 51.89 (-2.34)
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
GlobeNewswire - Tue Oct 14, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an amendment to the existing collaboration and license agreement (Collaboration Agreement) covering the United States (U.S.) and Canada for AMITIZA (lubiprostone) with Takeda Pharmaceutical Company Ltd. (Takeda). The amendment includes various modifications to the Collaboration Agreement including the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.
SCMP: 8.35 (+0.02)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 53.16 (+1.70), SCMP: 8.35 (+0.02), RDY: 50.72 (-0.32)
Unstable Angina Therapeutics Clinical Trials Market Review Report Available at MarketOptimizer.org
PRWeb - Sun Oct 12, 2:30PM CDT
Unstable angina is angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm. It is characterized by at least one of the following: Occurs at rest or minimal exertion and usually lasts less than 20 minutes (if nitroglycerin is not administered) Being severe and described as flank pain, and of new onset (i.e., within 1 month) Occurs with a crescendo pattern (more severe, prolonged, or increased frequency than previously). Fifty percent of people with unstable angina will have evidence of myocardial necrosis based on elevated cardiac serum markers such as creatine kinase isoenzyme (CK)-MB and troponin T or I, and thus have a diagnosis of non-ST elevation myocardial infarction. Clinical trial report, "Unstable Angina Global Clinical Trials Review, H2, 2014″ provides data on the Unstable Angina clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Unstable Angina. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Unstable Angina. Complete report available @ http://www.marketoptimizer.org/unstable-angin...-2014.html . Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated) Reasons To Buy Understand the dynamics of a particular indication in a condensed manner Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=11399 . Clinical Trial Overview of Top Companies: Sanofi Takeda Pharmaceutical Company Limited AstraZeneca PLC Pfizer Inc GlaxoSmithKline plc Biopure Corporation (Inactive) AtheroGenics, Inc. (Inactive) Alere Inc. Ablynx NV Clinical Trial Overview of Top Institutes / Government: National Heart, Lung, and Blood Institute China Academy of Chinese Medical Sciences Massachusetts General Hospital Karolinska Institute Nanjing Medical University Deutsches Herzzentrum Munchen Semnan University of Medical Sciences Kanagawa PTCA Conference Population Health Research Institute University of Oslo
PFE: 29.09 (+0.06), AZN: 71.43 (+0.67), GSK: 45.10 (-0.27), ALR: 39.12 (+1.55)
The Sixth Actos Verdict has been made in Favor of a Man Who Developed Bladder Cancer After Taking the Diabetes Medication, Parker Waichman LLP Comments
PRWeb - Fri Oct 10, 8:02AM CDT
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications reports that a jury has awarded another multi-million dollar settlement in a lawsuit brought over Takeda Pharmaceutical Co. Ltd.'s diabetes drug, Actos (pioglitazone). The case is Frances Wisniewski v. Takeda Pharmaceuticals America Inc. et al., case number 120702272, in the Philadelphia County Court of Common Pleas.
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA(R) and Company Receives Additional Paragraph IV Notice
Business Wire - Fri Oct 10, 12:51AM CDT
R-Tech Ueno (JASDAQ:4573):
SCMP: 8.35 (+0.02)
Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA
GlobeNewswire - Thu Oct 09, 3:45PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo, R-Tech Ueno, Ltd. (RTU), Takeda Pharmaceutical Company Limited (Takeda) and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc., (collectively, Par) that resolves patent litigation in the United States (U.S.) related to Sucampo's AMITIZA(lubiprostone) 8 mcg and 24 mcg soft gelatin capsules.
SCMP: 8.35 (+0.02)
Global Idiopathic (Essential) Hypertension Clinical Trials Review 2014 - Featuring the Top 10 Companies and 9 Institutues
M2 - Thu Oct 02, 5:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq9cbf/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials - Novartis AG - C. H. Boehringer Sohn AG & Co. KG - Takeda Pharmaceutical Company Limited - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Medionics International Inc - Bayer AG - GlaxoSmithKline plc - Pfizer Inc. - Les Laboratoires Servier SAS Overview of Top Institutes / Government - Institut de Recherches Internationales Servier - Regional Hospital Holstebro - National Heart, Lung, and Blood Institute - University of Erlangen-Nurnberg - University of Pavia - St. George's University of London - Central South University - Ehime University Graduate School of Medicine - Komono Kosei Hospital For more information visit http://www.researchandmarkets.com/research/vq9cbf/idiopathic
PFE: 29.09 (+0.06), MRK: 55.85 (-0.60), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Seattle Genetics-Takeda Reveal Impressive Adcetris Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 2:30PM CDT
Seattle Genetics, Inc. (SGEN) and partner Takeda announced positive top-line data from the randomized phase III AETHERA study on Adcetris for Hodgkin lymphoma.
MDVN: 101.18 (-1.57), SGEN: 36.37 (+0.98), GILD: 113.45 (+0.86)
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
Business Wire - Thu Sep 25, 12:15PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly announced today that Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations. Influenza B Infections Pipeline Review 2014 - 8 Companies & 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jk252h/influenza_b) has announced the addition of the "Influenza B Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Autoimmune Technologies, LLC - Takeda Pharmaceutical Company Limited - Crucell N.V. - Chimerix, Inc. - REPLICor Inc. - AltraVax Inc. - ContraFect Corporation - Humabs BioMed SA Drug Profiles - REP-9 - Influenza VLP Vaccine - Flufirvitide-3 - CF-403 - CR-8071 - CR-8033 - CR-9114 - Small Molecules for Influenza B - Monoclonal Antibody for Influenza B Infections - AL-18 - influenza B vaccine For more information visit http://www.researchandmarkets.com/research/jk...nfluenza_b
CMRX: 31.44 (-0.52)
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:10PM CDT
Novo Nordisk's (NVO) Saxenda received a favorable vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for chronic weight management.
AGN: 182.60 (+0.27), OREX: 4.19 (+0.14), NVO: 43.50 (-2.30)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
SNTA: 2.95 (+0.01), AMBI: 15.45 (+0.05), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), NVS: 92.35 (+2.14)
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
PSTI: 2.94 (+0.03), PFE: 29.09 (+0.06), ABBV: 60.93 (+0.44), PTIE: 2.07 (+0.12), ARRY: 3.84 (+0.27)
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
GSK: 45.10 (-0.27), SVA: 5.42 (+0.02), NVS: 92.35 (+2.14)
Takeda Responds to Judgment in Diabetes Drug Case
PR Newswire - Wed Sep 03, 12:37PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court has yet to rule on Takeda and Eli Lilly & Co.'s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award. LLY: 64.83 (-1.37)
Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
JNJ: 104.79 (+0.72), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), HZNP: 12.85 (+0.16), POZN: 8.82 (+0.08)
